Similar articles

• EFFICACY AND FREQUENCY OF INTRAVITREAL AFLIBERCEPT VERSUS BEVACIZUMAB FOR MACULAR EDEMA SECONDARY TO CENTRAL RETINAL VEIN OCCLUSION.

  Lotfy A, Solaiman KAM, Abdelrahman A, Samir A. Lotfy A, et al. Retina. 2018 Sep;38(9):1795-1800. doi: 10.1097/IAE.0000000000001782. Retina. 2018. PMID: 28767552 Clinical Trial.
• The effect of switching ranibizumab to aflibercept in refractory cases of macular edema secondary to ischemic central vein occlusion.

  Lehmann-Clarke L, Dirani A, Mantel I, Ambresin A. Lehmann-Clarke L, et al. Klin Monbl Augenheilkd. 2015 Apr;232(4):552-5. doi: 10.1055/s-0035-1545783. Epub 2015 Apr 22. Klin Monbl Augenheilkd. 2015. PMID: 25902119
• Effect of aflibercept on refractory macular edema associated with central retinal vein occlusion.

  Călugăru D, Călugăru M. Călugăru D, et al. Can J Ophthalmol. 2017 Feb;52(1):137. doi: 10.1016/j.jcjo.2016.11.019. Epub 2017 Jan 5. Can J Ophthalmol. 2017. PMID: 28237141 No abstract available.
• Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study.

  Korobelnik JF, Holz FG, Roider J, Ogura Y, Simader C, Schmidt-Erfurth U, Lorenz K, Honda M, Vitti R, Berliner AJ, Hiemeyer F, Stemper B, Zeitz O, Sandbrink R; GALILEO Study Group. Korobelnik JF, et al. Ophthalmology. 2014 Jan;121(1):202-208. doi: 10.1016/j.ophtha.2013.08.012. Epub 2013 Sep 29. Ophthalmology. 2014. PMID: 24084497 Clinical Trial.
• Aflibercept: A Review in Macular Oedema Secondary to Branch Retinal Vein Occlusion.

  Hoy SM. Hoy SM. Drugs Aging. 2017 May;34(5):393-400. doi: 10.1007/s40266-017-0458-6. Drugs Aging. 2017. PMID: 28365905 Review.